🔴 Chemours is trading 5.2% down today after Morgan Stanley cut its target to $18

Chemours is trading at $14.93 (-5.21%) after Morgan Stanley reduced its price target to $18 from $21 while maintaining an Equalweight rating on August 10, 2026.

• Recent second-quarter earnings showed $0.42 adjusted EPS and $1.59 billion revenue, below estimates, pressuring shares on August 5.
• Management forecast third-quarter EBITDA of $175 million-$205 million, signaling continued pressure.
• Broader markets are only modestly weaker, so company-specific sentiment appears to be the primary driver.